STOCK TITAN

Treace Medical Concepts (TMCI) Stock News, Apr-Sep 2021

TMCI NASDAQ

Treace Medical Concepts, Inc. develops and markets orthopaedic medical devices for the surgical treatment of bunions and related midfoot deformities. Its updates center on the Lapiplasty® 3D Bunion Correction procedure and related technologies used by surgeons, ambulatory surgery centers and hospitals.

Recurring news themes for TMCI include quarterly and annual financial results, revenue guidance, surgeon adoption, cash and liquidity updates, product introductions and clinical data. Company announcements also cover additions to the bunion and midfoot technology portfolio, including SuperBite™ Compression Screw System, Lapiplasty® Lightning™ technology, SpeedMTP® and IntelliGuide® PSI, as well as patent portfolio activity and presentations at foot and ankle surgery conferences.

Rhea-AI Summary

Treace Medical Concepts (Nasdaq: TMCI), a pioneering orthopaedic medical device company, announced new data will be presented at the 2021 AOFAS Annual Meeting on September 22-25. The presentation will feature an interim analysis from the ALIGN3D™ clinical study, which evaluates the Lapiplasty® 3D Bunion Correction™ procedure. Lead author Dr. Dane Wukich will discuss outcomes from this multicenter study, focusing on patient recovery and radiographic results. The study aims to confirm effective bunion correction over a 24-month follow-up with 173 enrolled patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.43%
Tags
none
-
Rhea-AI Summary

Treace Medical Concepts (TMCI) reported Q2 2021 revenue of $20.7 million, marking a 167% increase compared to Q2 2020. The gross margin improved to 80.9%, up 780 basis points year-over-year. The rise in revenue is attributed to more Lapiplasty® procedure kits sold and a growing customer base. Despite higher revenues, the net loss for the quarter increased to ($5.1 million), or ($0.10) per share, compared to ($2.1 million), or ($0.06) per share last year. The company anticipates full-year revenue between $90 million and $95 million, reflecting a growth of 57% to 65%.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.34%
Tags
-
Rhea-AI Summary

Treace Medical Concepts (NasdaqGS: TMCI) will announce its second quarter 2021 financial results on August 5, 2021, after the market closes. A conference call led by management will commence at 4:30 p.m. ET to discuss the results. The company is known for its Lapiplasty® 3D Bunion Correction™ system, which addresses bunion deformities. Investors can join the call by dialing (888) 708-0264 or (720) 405-2122 for international access. The call will also be webcasted live and archived on their investor relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.20%
Tags
conferences earnings
Rhea-AI Summary

Treace Medical Concepts (TMCI) reported significant first-quarter 2021 financial results, achieving $18.7 million in revenue, a 66.2% increase from last year. Gross margin improved to 82.2%, up 340 basis points year-over-year, driven by higher sales of the Lapiplasty Procedure Kits. Despite a net loss of $2.6 million or ($0.07) per share, the company anticipates a full-year revenue range of $87 million to $92 million, indicating 52% to 60% growth from fiscal 2020. Cash and equivalents stood at $16.2 million as of March 31, 2021, excluding IPO proceeds.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.27%
Tags
-
Rhea-AI Summary

Treace Medical Concepts (TMCI) announced positive interim results from the ALIGN3D clinical study at the ACFAS Annual Scientific Conference. The study evaluated 128 participants undergoing the Lapiplasty 3D Bunion Correction procedure. Key findings include an early weight-bearing average of 8.3 days, a 1.4% recurrence rate at 12 months, and significant improvements in patient-reported pain and quality of life. The study aims to assess long-term outcomes and has completed enrollment, with final results expected in 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.75%
Tags
-
Rhea-AI Summary

Treace Medical Concepts (TMCI) announced it will release its Q1 2021 financial results on May 25, 2021, after market close. A conference call hosted by management will take place at 4:30 p.m. ET to discuss these results. Investors can access the call by dialing (833) 730-3977 (domestic) or (720) 405-2122 (international) with Conference ID: 1157038. The company specializes in surgical treatments for bunions through its patented Lapiplasty® 3D Bunion Correction™ system, aimed at enhancing patient recovery and addressing the root causes of bunion deformities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.44%
Tags
conferences earnings
Rhea-AI Summary

Treace Medical Concepts (TMCI) announced that interim results of its ALIGN3D™ clinical study will be presented at the ACFAS Scientific Conference on May 19, 2021. The study evaluates the effectiveness of the Lapiplasty® 3D Bunion Correction™ in treating hallux valgus, involving 173 patients across seven sites. Key endpoints include recurrence of the bunion deformity and patient-reported outcomes after two years. The final follow-up for primary endpoints is expected in the first half of 2023, indicating ongoing commitment to advancing surgical treatment standards.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.97%
Tags
none
-
Rhea-AI Summary

Treace Medical Concepts, Inc. (Nasdaq: TMCI) announced its upsized initial public offering pricing of 11,250,000 shares at $17.00 each, aiming for gross proceeds of approximately $106.3 million. Of these shares, 6,250,000 will be sold by Treace, while 5,000,000 are from selling stockholders. Additionally, underwriters have a 30-day option to purchase up to 1,687,500 additional shares. Trading is set to commence on April 23, 2021, with the closing expected by April 27, 2021, following standard conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Treace Medical Concepts (Nasdaq: TMCI) announced an upsized initial public offering (IPO) of 11,250,000 shares, priced at $17.00 each, aiming to raise approximately $106.3 million before expenses. Of these, 6,250,000 shares are offered by Treace while 5,000,000 shares are from selling stockholders. The offering includes a 30-day option for underwriters to purchase an additional 1,687,500 shares. Trading on the Nasdaq is set to start on April 23, 2021, with the closing anticipated on April 27, 2021, pending customary conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags

FAQ

What is the current stock price of Treace Medical Concepts (TMCI)?

Treace Medical Concepts (TMCI) last closed at $4.53.

What is the market cap of Treace Medical Concepts (TMCI)?

The market cap of Treace Medical Concepts (TMCI) is approximately $297.0M.